


[For Immediate Release]



中國抗體製藥有限公司
SinoMab BioScience Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3681)

**SinoMab Awarded the "Best Small and Medium-Cap Company" in the
"8th Zhitong Caijing Listed Company Awards"
Development Potential Recognised by The Capital Market**



(6 December 2023 – Hong Kong) A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that the Company was awarded the "Best Small and Medium-Cap Company" in the "8th Zhitong Caijing Listed Company Awards" held in Shenzhen. Ms. Esther LI Sin Ting, company secretary of SinoMab, attended the award ceremony on behalf of the Company.

The "8th Zhitong Caijing Listed Company Awards" was jointly organized by Zhitongcaijing.com, China's leading information platform focusing on Hong Kong and US stock markets, and RoyalFlush(同花順). At the awards ceremony, Zhitong Caijing selected 27 major awards. One of these awards was the "Best Small and Medium-Cap Company," which aimed to acknowledge small and medium-cap listed companies that have a business layout aligned with the market development pattern and demonstrate good current operation momentum and growth potential. Additionally, the Company was previously honored with the "Most Popular Newly Listed Company" and the "Most Valuable Pharmaceutical and Medical Company" at the "Hong Kong Golden Stocks Awards Ceremony" held by relevant organisers in the past, which was a testament to the recognition of the capital market.

SinoMab won the "Best Small and Medium-Cap Company" award, which not only reflected the attention of

the industry and investors to the biotechnology industry, and also demonstrated the capital market’s full recognition of the Company’s operational strategy, business development and growth potential. As the first locally-listed biopharmaceutical company in Hong Kong, SinoMab is dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases. The company has several first-in-target and first-in-class drug candidates, some of which have already entered the clinical stage. Its flagship product, SM03 (Suciraslimab), has had its biologics license application (“BLA”) in the treatment of rheumatoid arthritis (“RA”), accepted by the National Medical Products Administration of China (the “NMPA”) on 5 September 2023. It has officially entered the countdown stage of achieving commercial profitability. The Company is also actively mapping out its long-term development plan and has initially built a marketing team this year to prepare for commercialisation.

“Zhitong Caijing Listed Company Awards” has become the world’s authoritative selection event for Hong Kong and US listed companies, and is widely recognised by investors around the world as a reliable indicator. This prestigious award includes participation from listed companies in Hong Kong and the United States, spanning traditional industries such as energy, finance, automobile, and industrial manufacturing, as well as emerging industries that are leading China's economic transformation, such as telecommunications, chip manufacturing, internet, and medical and pharmaceuticals. This award demonstrates that the Company’s capital market performance and growth potential are promising by investors and authoritative industry institutions, and also helps enhance the exposure of the Company in the capital market with authoritative awards.

Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of the Company, said, “The Company is deeply honoured to receive the “Best Small and Medium-Cap Company” award in this selection, which reflects the high recognition of the Company’s value, management and development potential by professional institutions of capital market, and it also serves as an encouragement for the Company. In the future, the Company will stay true to our original aspiration, continue to adhere to independent innovation, deepen the development of immunological therapy, and spare no effort to provide more effective treatment options for patients around the world. At the same time, we will actively promote commercialization process, and strive to repay investors’ trust with better performance and create value for shareholders.”



About SinoMab BioScience Limited

SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company's flagship product SM03(Suciraslimab) is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer's disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.

About “8th Zhitong Caijing Capital Market Annual Conference”

The “8th Zhitong Caijing Capital Market Annual Conference” jointly organized by Zhitongcaijing.com, China’s leading information platform focusing on Hong Kong and US stock markets, and RoyalFlush(同花順). The professional financial roadshow live broadcast platform “Roadshowing” provided roadshow support, and was exclusively organised by Shenzhen Donggrinuan yang Culture Communication Co., Ltd. The conference will be held in Shenzhen and Hong Kong, the strategic hinterland of the Guangdong-Hong Kong-Macao Greater Bay Area, under the theme of “Light of Sunrise, Embracing the New Central”. The conference will discuss with the investment community opinion leaders and economists, 300+ senior management of A-share listed companies in Hong Kong and the United States, 100+USD funds, 1000+professional investors and high-net-worth individual investors about the hot topics of capital market investment, and welcome the new light of capital market investment in 2024.

This press release is issued by **Financial PR (HK) Limited** on behalf of **SinoMab BioScience Limited**. For further information, please contact:

Financial PR (HK) Limited

Contact: Ms. Chloe Chiu / Ms. Serena Zhang / Ms. Romy Hong

Email: sinomab@financialpr.hk

Tel: (852) 2610 0846

Fax: (852) 2610 0842